NorthStrive Licenses Myostatin-Probiotic Tech to Modulant for Animal Health
Event summary
- NorthStrive Biosciences signed a definitive license agreement with Modulant Biosciences on February 11, 2026 for EL-22 and EL-32, myostatin-engineered probiotics targeting muscle preservation in animals.
- The deal grants Modulant exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize products derived from these technologies as feed additives.
- Modulant will handle all development, regulatory, and commercialization activities under the agreement.
- EL-22 and EL-32 target myostatin and activin-A pathways, key regulators of muscle development and metabolic efficiency in animals.
The big picture
This deal positions NorthStrive's probiotic technology within Modulant's veterinary innovation pipeline, targeting growing demand for animal performance and wellness solutions. The agreement reflects increasing industry focus on muscle health as a key differentiator in livestock productivity and companion animal care. Success will depend on Modulant's execution capabilities and the broader market's receptiveness to myostatin-targeting probiotics.
What we're watching
- Commercialization Pace
- How quickly Modulant can advance EL-22 and EL-32 through development and regulatory approvals to reach market.
- Market Acceptance
- Whether animal health products derived from these technologies will gain traction among livestock and companion animal owners.
- Pipeline Expansion
- The potential for shared IP improvements to create additional value beyond the current agreement.
Related topics